Form 4: UroGen Pharma Director's Future RSU Conversion

UroGen Pharma Ltd. Director Cynthia M. Butitta reported a future transaction to acquire 2,000 ordinary shares through the exercise of restricted stock units under a 10b5-1 plan.

Summary

• Cynthia M. Butitta, a Director of UroGen Pharma Ltd. (URGN), filed a Form 4 reporting a scheduled transaction.
• The transaction is set to occur on November 26, 2025, and involves the exercise of 2,000 Restricted Stock Units (RSUs).
• Upon exercise, 2,000 ordinary shares of UroGen Pharma Ltd. will be acquired by Ms. Butitta.
• This transaction is made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged equity management strategy.
• Following this scheduled transaction, Ms. Butitta will directly own 2,000 ordinary shares and beneficially own 6,000 derivative securities (RSUs).

Sentiment

Score: 5

Explanation: The filing is a routine report of a scheduled insider transaction (RSU exercise) under a 10b5-1 plan, which is neutral in sentiment. It does not convey positive or negative news about the company's operational or financial performance.

Positives

• The transaction is part of a pre-planned Rule 10b5-1(c) plan, indicating a structured and compliant approach to insider equity management.
• The acquisition of ordinary shares, even through RSU conversion, increases the director's direct equity stake in the company, aligning interests with shareholders.

Future Outlook

This filing reports a pre-scheduled future transaction by a director, indicating planned equity management rather than a forward-looking statement on company performance or strategy.

Industry Context

This is a routine insider transaction filing common across all publicly traded companies, particularly for directors and executives managing their equity compensation through pre-arranged 10b5-1 plans. It reflects standard corporate governance practices for equity awards.

Stakeholder Impact

• Shareholders: Provides transparency regarding a director's future equity holdings and planned transactions.
• Employees, Customers, Suppliers, Creditors: No direct impact from this filing.

Key Dates

Keywords

UroGen Pharma, URGN, Form 4, Insider Transaction, Restricted Stock Units, RSU, Director, Equity, 10b5-1 Plan, Cynthia M. Butitta